Get the Stockscreener App
1.73
2.37%
0.04
Acrivon Therapeutics Inc stock is traded at $1.73, with a volume of 301.94K.
It is up +2.37% in the last 24 hours and down -6.99% over the past month.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.
See More
Previous Close:
$1.69
Open:
$1.73
24h Volume:
301.94K
Relative Volume:
0.68
Market Cap:
$74.05M
Revenue:
-
Net Income/Loss:
$-77.27M
P/E Ratio:
-0.8642
EPS:
-2.0019
Net Cash Flow:
$-66.29M
1W Performance:
+15.33%
1M Performance:
-6.99%
6M Performance:
+3.59%
1Y Performance:
+36.22%
1-Day Range:
$1.71
$1.7599
1-Week Range:
$1.482
$1.7599
52-Week Range:
$1.2002
$3.56
Acrivon Therapeutics Inc Stock (ACRV) Company Profile
Name
Acrivon Therapeutics Inc
Sector
Industry
Phone
617-207-8979
Address
480 ARSENAL WAY, SUITE 100, WATERTOWN
Compare ACRV vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACRV
Acrivon Therapeutics Inc
|
1.73 | 66.77M | 0 | -77.27M | -66.29M | -2.0019 |
VRTX
Vertex Pharmaceuticals Inc
|
496.07 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
784.36 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
865.04 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
205.15 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
348.27 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Acrivon Therapeutics Inc Stock (ACRV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-05-25 | Resumed | Piper Sandler | Overweight |
| Jan-31-25 | Initiated | KeyBanc Capital Markets | Overweight |
| Sep-16-24 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Apr-29-24 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Mar-01-24 | Initiated | JMP Securities | Mkt Outperform |
| Dec-15-23 | Resumed | Jefferies | Buy |
| Oct-05-23 | Initiated | Maxim Group | Buy |
| Jun-02-23 | Initiated | Oppenheimer | Outperform |
| May-08-23 | Initiated | BMO Capital Markets | Outperform |
| Apr-27-23 | Initiated | Ladenburg Thalmann | Buy |
| Apr-20-23 | Initiated | H.C. Wainwright | Buy |
| Dec-12-22 | Initiated | Cowen | Outperform |
| Dec-12-22 | Initiated | Jefferies | Buy |
| Dec-12-22 | Initiated | Piper Sandler | Overweight |
View All
Acrivon Therapeutics Inc Stock (ACRV) Latest News
Acrivon Therapeutics Inc (ACRV) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
ACRV|Acrivon Therapeutics Inc|Price:1.610|Chg%:+0.010 - TradingKey
Acrivon Therapeutics Inc (ACRV) Balance Sheet - TradingKey
ACRV|Acrivon Therapeutics Inc|Price:1.570|Chg%:-0.030 - TradingKey
TradingKey - TradingKey
Acrivon Therapeutics Inc (ACRV) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Acrivon Therapeutics Inc (ACRV) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Acrivon Therapeutics Inc (ACRV) Institutional Confidence - TradingKey
Acrivon Therapeutics Inc (ACRV) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Acrivon Therapeutics Inc (ACRV) Valuation: PE, PB & Fair Value Analysis - TradingKey
Acrivon Therapeutics Inc (ACRV) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Acrivon Therapeutics Inc (ACRV) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
ACRV|Acrivon Therapeutics Inc|Price:1.525|Chg%:-0.035 - TradingKey
Form 4 Acrivon Therapeutics Inc For: 24 July By Investing.com - Investing.com South Africa
Acrivon Therapeutics CLO Mary Miller sells $1,008 in company stock - Investing.com
Acrivon Therapeutics CLO Mary Miller sells $1,008 in company stock By Investing.com - Investing.com Australia
Insider tax-withholding share sale at Acrivon Therapeutics (NASDAQ: ACRV) - Stock Titan
Acrivon Therapeutics (ACRV) Slips Slightly, Holding Near Key Support ZoneRegression Channel - dars.gov.et
ACRV Stock Price, Quote & Chart - ChartMill
Why Is Acrivon Therapeutics (NASDAQ:ACRV) Fueling Nasdaq Talk? - Kalkine Media
Acrivon Therapeutics (ACRV) Holds Steady Near Support Amid Low-Volume TradingVolume Spike Alerts - dars.gov.et
Acrivon highlights AP3 platform and clinical pr... - Pluang
Acrivon to Highlight the Power of its AP3 Platform for - GlobeNewswire
Trading Systems Reacting to (ACRV) Volatility - Stock Traders Daily
Acrivon Therapeutics trades below cash value de... - Pluang
Acrivon Therapeutics: Priced For Failure, Built For Precision (NASDAQ:ACRV) - Seeking Alpha
ACRVAcrivon Therapeutics Inc Options - Finviz
Price to book forward of Acrivon Therapeutics, Inc. – NASDAQ:ACRV - TradingView
Enterprise value to EBITDA forward of Acrivon Therapeutics, Inc. – NASDAQ:ACRV - TradingView
Price to sales forward of Acrivon Therapeutics, Inc. – NASDAQ:ACRV - TradingView
Price to earnings forward of Acrivon Therapeutics, Inc. – NASDAQ:ACRV - TradingView
Acrivon Therapeutics, Inc. Actuals & Estimates (NASDAQ:ACRV) - TradingView
ACRV Forecast — Price Target — Prediction for 2027 - TradingView
Acrivon Therapeutics (ACRV) Slips 2.47% in Low-Volume Trade, Testing Key Support at $1.5Sector ETF Flow - dars.gov.et
Form 4 Acrivon Therapeutics Inc For: 22 June By Investing.com - Investing.com South Africa
Director-linked RA Capital funds receive 20,275 Acrivon (ACRV) stock options at $1.52 - Stock Titan
Acrivon (NASDAQ: ACRV) director granted 20,275 stock options at $1.52 - Stock Titan
Acrivon Therapeutics (ACRV) director Sharon Shacham awarded 20,275 stock options - Stock Titan
Acrivon Therapeutics (ACRV) director receives 20,275 stock options at $1.52 strike - Stock Titan
Acrivon Therapeutics (ACRV) director granted options on 20,275 shares - Stock Titan
Acrivon Therapeutics (ACRV) director awarded 20,275-share option for RA Capital funds - Stock Titan
Acrivon Therapeutics (ACRV) director receives 20,275 stock options at $1.52 - Stock Titan
Acrivon Shareholders Approve Expanded Equity Plan and Directors - The Globe and Mail
Acrivon Therapeutics Stockholders Approve Amended 2022 Equity Incentive Plan and Elect New Directors – June 2026 - Minichart
Acrivon Therapeutics shareholders approve equity plan changes and director elections - Investing.com UK
Acrivon Therapeutics shareholders approve equity plan changes and director elections By Investing.com - Investing.com India
Acrivon amends equity plan, shareholders approve 3,000,000-share increase - TradingView
Acrivon Therapeutics (ACRV) shareholders approve larger equity plan and elect directors - Stock Titan
Acrivon Therapeutics Inc Stock (ACRV) Financials Data
Revenue
Net Income
Cash Flow
EPS
Acrivon Therapeutics Inc Stock (ACRV) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Miller Mary | Chief Legal Officer |
Jul 21 '26 |
Sale |
1.76 |
573 |
1,008 |
82,194 |
| Blume-Jensen Peter | President and CEO |
Jan 14 '26 |
Buy |
1.68 |
49,000 |
82,124 |
2,095,771 |
| Levy Adam D. | Chief Financial Officer |
Jan 14 '26 |
Buy |
1.70 |
8,832 |
14,999 |
20,983 |
| Devroe Eric | Chief Operating Officer |
Jan 13 '26 |
Buy |
1.72 |
10,000 |
17,218 |
75,308 |
1.84%
0.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):